Effect of 50 μg anti-MPO versus anti-OVA on circulating leukocyte counts, percentage of circulating neutrophils, and MPO levels in spleen and lung
| . | Anti-OVA . | Anti-MPO . |
|---|---|---|
| Circulating leukocyte count, cells/×10−6/mL, n = 5/gp | 5.6 ± 0.7 | 1.7 ± 0.5* |
| % of neutrophils in cytospun blood samples, n = 5/gp | 16.8 ± 1.8 % | 0.8 ± 0.5%* |
| Splenic MPO activity 5 min after anti-MPO, U/g, n = 7/gp | 24.8 ± 8.9 | 53.5 ± 9.9† |
| Lung MPO activity 5 min after anti-MPO, U/g, n = 7/gp | 2.5 ± 0.6 | 4.0 ± 1.1 (NS) |
| Splenic MPO activity 60 min after anti-MPO, U/g, n = 7/gp | 19.3 ± 3.2 | 19.4 ± 3.0 (NS) |
| Lung MPO activity 60 min after anti-MPO, U/g, n = 7/gp | 10.9 ± 2.1 | 8.6 ± 1.9 (NS) |
| . | Anti-OVA . | Anti-MPO . |
|---|---|---|
| Circulating leukocyte count, cells/×10−6/mL, n = 5/gp | 5.6 ± 0.7 | 1.7 ± 0.5* |
| % of neutrophils in cytospun blood samples, n = 5/gp | 16.8 ± 1.8 % | 0.8 ± 0.5%* |
| Splenic MPO activity 5 min after anti-MPO, U/g, n = 7/gp | 24.8 ± 8.9 | 53.5 ± 9.9† |
| Lung MPO activity 5 min after anti-MPO, U/g, n = 7/gp | 2.5 ± 0.6 | 4.0 ± 1.1 (NS) |
| Splenic MPO activity 60 min after anti-MPO, U/g, n = 7/gp | 19.3 ± 3.2 | 19.4 ± 3.0 (NS) |
| Lung MPO activity 60 min after anti-MPO, U/g, n = 7/gp | 10.9 ± 2.1 | 8.6 ± 1.9 (NS) |
Samples were removed 5 minutes after intravenous administration of 50 μg of either anti-MPO or anti-OVA, except for the 60-minute samples for splenic and lung MPO activity, which were removed 60 minutes after antibody administration.
NS indicates not significant relative to anti-OVA.
P < .001 vs anti-OVA.
P < .05 vs anti-OVA.